Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.

OBJECTIVE This study quantified the overall merit of adjunctive aripiprazole in major depressive disorder (MDD). METHODS Global benefit-risk (GBR) analysis quantified the benefit and risk differences between adjunctive aripiprazole and antidepressant (ADT) monotherapy. Three hundred and fifty six patients receiving ADT monotherapy and 366 patients receiving ADT and adjunctive aripiprazole (2-20 mg/day) were included. Efficacy measures included the Montgomery-Asberg depression rating scale (MADRS) Total score response (> or =50% reduction) and remission (response plus Total score < or = 10). Treatment-emergent adverse events were classified by severity. GBR ratio measures evaluated the relative benefit of adjunctive aripiprazole. Logistic regression models tested the effect of adjunctive aripiprazole on GBR and were used to identify predictors of net benefit and potential factors affecting the adjunctive aripiprazole treatment effect. RESULTS For MADRS-defined response and remission, the relative gain of adjunctive aripiprazole versus ADT monotherapy was 1.46 (p = 0.044) and 1.43 (p = 0.085), respectively. Gender, current escitalopram, duration of current episode, and baseline body mass index are potential factors affecting the adjunctive aripiprazole treatment effect. CONCLUSIONS Compared with ADT monotherapy, adjunctive aripiprazole was associated with an improved benefit-risk profile in MDD.

[1]  R. Entsuah,et al.  Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.

[2]  C Chuang-Stein,et al.  Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.

[3]  Aripiprazole augmentation for treatment of patients with inadequate antidepressants response , 2007, Depression and anxiety.

[4]  R. Berman,et al.  The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.

[5]  M. Pollack,et al.  Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients , 2005, International clinical psychopharmacology.

[6]  M. Fava,et al.  Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice , 2006, Psychotherapy and Psychosomatics.

[7]  Maurizio Fava,et al.  Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.

[8]  P. Masand,et al.  An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. , 2006, Primary care companion to the Journal of clinical psychiatry.

[9]  M. Fava,et al.  The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.

[10]  M. Fava,et al.  Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. , 2005, The Journal of clinical psychiatry.

[11]  M. Fava,et al.  Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. , 2008, Primary care companion to the Journal of clinical psychiatry.

[12]  C. Nemeroff,et al.  Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. , 2005, The Journal of clinical psychiatry.

[13]  M. Thase,et al.  A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. , 2008, Journal of psychiatric research.

[14]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[15]  R. Shelton,et al.  Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. , 2007, The Journal of clinical psychiatry.

[16]  R. Tamura,et al.  Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method , 2008, Pharmaceutical statistics.

[17]  Richard Entsuah,et al.  Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.